Dr. Kindsfather on the Evolution of Reflex Testing in Lung Cancer

Scott K. Kindsfather, MD, discusses the evolution of reflex testing in lung cancer.

Scott K. Kindsfather, MD, medical director, Medical Oncology, Capital Health, discusses the evolution of reflex testing in lung cancer.

Currently, all resected specimens are being tested for PD-L1 levels and EGFR mutations, and the parameters of reflex testing will be moving targets going forward, Kindsfather says. As treatments currently being utilized in advanced settings are shifted up in the treatment paradigm, reflex testing will need to cover additional areas for new up-front therapies, Kindsfather concludes.

This information has been relayed to pathologists, and reflex testing will need to remain adaptive to keep pace with the treatment landscape, Kindsfather concludes.

Related Videos
Consuelo Bertossi, MD
Michael R. Grunwald, MD, FACP
Sundar Jagannath, MBBS
Kevin Kalinsky, MD, MS,
Aaron Gerds, MD
Paolo Tarantino, MD
Chinmay Jani, MD, clinical fellow, Hematology & Oncology, Sylvester Comprehensive Cancer Center at the University of Miami/Jackson Memorial Hospital
Shella Saint Fleur-Lominy, MD, PhD
Benjamin Levy, MD
Nader Sanai, MD, chief, Neurosurgical Oncology, director, Ivy Brain Tumor Center, Barrow Neurological Institute